Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in relapsed or refractory chronic lymphocytic leukemia

Update Il y a 4 ans
Reference: EUCTR2006-006694-24

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Phase I, Dose escalation • determination of the maximum tolerated dose (MTD) of FBTA05 in patients with relapsed or refractory chronic lymphocytic leukemia (B-CLL). Phase II, Efficacy • evaluation of the preliminary efficacy of FBTA05 in patients with relapsed or refractory chronic lymphocytic leukemia with regard to objective response rate (CR, PR)


Inclusion criteria

  • Relapsed or Refractory Chronic Lymphocytic Leukemia

Links